TheraRadar
Landscape / Infectious Disease
Data updated: Jun 28, 2026

H. pylori Clinical Trial Landscape

H. pylori is being studied across 205 clinical trials registered since 2008, with 56 programs currently active.

The competitive pipeline includes 14 active Phase 3 trials, 7 active Phase 2 trials, and 0 active Phase 1 trials. Top industry sponsors include ARJ Medical, Inc., Catalysis SL, Xuanzhu Biopharmaceutical Co., Ltd..

Trial activity

56 active / 205 total since 2008
Active by phase 14 Ph3 / 49 7 Ph2 / 19 0 Ph1 / 14 35 Ph4 / 123

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
ARJ Medical, Inc. 2 1 0
Catalysis SL 1 0 0
Xuanzhu Biopharmaceutical Co., Ltd. 1 0 0
TenNor Therapeutics (Suzhou) Limited 0 6 0
Takeda 0 4 0
Meridian Bioscience, Inc. 0 4 0
HK inno.N Corporation 0 3 0

How the field has grown

New-trial starts peaked in 2024 (20 registered); 2025 saw 17. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (33 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
8
2017
10
2018
18
2019
11
2020
13
2021
13
2022
18
2023
14
2024
20
2025
17
2026
10

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (1)
112
2017 (3)
350
2018 (2)
601
2019 (1)
1,046
2020 (5)
102
2021 (1)
51
2022 (5)
126
2023 (2)
418
2024 (5)
461
2025 (4)
155
2026 (4)
458

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT07576959 RECRUITING
Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
National Taiwan University Hospital n=990
NCT07104318 NOT YET RECRUITING
Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans
VA Office of Research and Development n=360
NCT07275827 NOT YET RECRUITING
Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
Tanta University n=88
NCT06734260 RECRUITING
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
Eighth Affiliated Hospital, Sun Yat-sen University n=477
NCT07246681 ACTIVE NOT RECRUITING
Lignin in Treatment of Helicobacter Pylori Infection
Zagazig University n=70
NCT07242456 RECRUITING
Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication
First People's Hospital of Hangzhou n=240
NCT06964334 NOT YET RECRUITING
The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection
Assiut University n=70
NCT06760065 NOT YET RECRUITING
Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Sixth Affiliated Hospital, Sun Yat-sen University n=316
NCT02112214 ACTIVE NOT RECRUITING
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
National Cancer Center, Korea n=5,224
NCT06591494 NOT YET RECRUITING
The Efficacy of Quadruple Therapy Containing Sodium Bicarbonate as the Primary Treatment for Helicobacter Pylori Infection
Second Affiliated Hospital, School of Medicine, Zhejiang University n=855
NCT05276557 RECRUITING
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
ARJ Medical, Inc. n=40
NCT05681689 RECRUITING
PyloPlus Urea Breath Test System Post Therapy Efficacy Confirmation Study
ARJ Medical, Inc. n=77
NCT04415983 RECRUITING
Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children
Tanta University n=100
NCT07606833 NOT YET RECRUITING
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
Xuanzhu Biopharmaceutical Co., Ltd. n=556
NCT06340724 COMPLETED
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Nanjing First Hospital, Nanjing Medical University n=104
NCT06751121 COMPLETED
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
Daewoong Pharmaceutical Co. LTD. n=461
NCT06576882 COMPLETED
7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
Alexandria University n=326
NCT06414707 COMPLETED
Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori
Ain Shams University n=320
NCT04473079 COMPLETED
Efficacy and Safety of Lacidofil® STRONG as an Adjuvant for Helicobacter Pylori Treatment in Non-ulcer Dyspepsia
Lallemand Health Solutions n=90
NCT05297695 COMPLETED
Helicobacter Pylori Eradication Therapy for Epileptic Children
Sohag University n=126
NCT05577468 COMPLETED
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. n=561
NCT05719831 COMPLETED
Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection
Sixth Affiliated Hospital, Sun Yat-sen University n=516
NCT03779074 COMPLETED
Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
Kaohsiung Veterans General Hospital. n=918
NCT06101420 COMPLETED
Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication
Ain Shams University n=232
NCT04198363 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
Takeda n=510
NCT05863858 COMPLETED
Eradication of H. Pylori Infection With Moxifloxacin
Iyad Naeem Muhammad, PhD n=162
NCT05861687 COMPLETED
Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children
Finni Kollins n=51
NCT02528721 COMPLETED
Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
Meridian Bioscience, Inc. n=282
NCT02010112 COMPLETED
Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori
Meridian Bioscience, Inc. n=193
NCT02905825 COMPLETED
Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics
Meridian Bioscience, Inc. n=54
NCT04167670 COMPLETED
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
Phathom Pharmaceuticals, Inc. n=1,046
NCT03317223 COMPLETED
A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
HK inno.N Corporation n=350
NCT04128917 COMPLETED
Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT
HK inno.N Corporation n=102
NCT03498456 COMPLETED
Triple Therapy With Tegoprazan in H. Pylori Positive Patients
HK inno.N Corporation n=284
NCT02557932 COMPLETED
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
National Cancer Center, Korea n=352
NCT03198507 COMPLETED
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
RedHill Biopharma Limited n=455
NCT01980095 COMPLETED
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
RedHill Biopharma Limited n=119
NCT02827942 COMPLETED
Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication
Hamamatsu University n=112
NCT02767479 COMPLETED
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
Hamamatsu University n=200
NCT00712413 WITHDRAWN
Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori
Forest Laboratories
NCT02726269 COMPLETED
Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.
Asofarma de México S.A de C.V. n=230
NCT01933659 COMPLETED
Anti-H. Pylori Effect of Deep See Water
National Taiwan University Hospital n=54
NCT02004197 COMPLETED
Quadruple and Phytomedicine-based Therapies in H. Pylori Infection
Hafiz Muhammad Asif n=176
NCT01505127 COMPLETED
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
Takeda n=650
NCT01456728 COMPLETED
Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects on Proton Pump Inhibitors
St Marina University Hospital, Varna, Bulgaria n=56
NCT01730352 COMPLETED
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
Federal University of São Paulo n=100
NCT01061437 COMPLETED
S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)
SWOG Cancer Research Network n=1,859
NCT01544517 COMPLETED
5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection
University of Campania Luigi Vanvitelli n=180
NCT01131026 COMPLETED
Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Deva Holding A.S. n=60

Full H. pylori Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only